Sign in
4

Changes in Ownership

Aclaris Therapeutics, Inc. Filed Acc 0001209191-23-006969

Options or other derivatives

  • Chief Financial Officer acquired 135,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Balthaser Kevin Chief Financial Officer 2023-02-01 Grant or award · Employee Stock Option (Right to Buy) +105,000 105,000 D
Balthaser Kevin Chief Financial Officer 2023-02-01 Grant or award · Restricted Stock Units +30,000 30,000 D
Loading xslF345X03/doc4.xml…